| Treating patients with acute gastrointestinal bleeding or rebleeding. | |
| | |
MedLine Citation:
|
PMID: 14587962 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Despite advances in medical management, gastrointestinal bleeding remains a substantial cause of morbidity and mortality. At risk are patients with history of the event, those taking nonsteroidal antiinflammatory agents, and those with active peptic ulcer disease. Endoscopy may be performed for diagnosis and treatment. Antisecretory therapy may be employed to control gastric acid secretion, treat active peptic ulcer disease, and control symptoms such as diarrhea and abdominal pain. Options for antisecretory therapy include histamine2-receptor antagonists (H2RAs) that target the histamine pathway, and proton pump inhibitors (PPIs) that target the final step in acid secretion. The H2RAs generally are ineffective at reaching a target pH of 6 in patients with gastrointestinal bleeding because of tachyphylaxis. The PPIs are more effective and do not lead to tachyphylaxis. With the availability of an intravenous PPI, pantoprazole, options for managing hospitalized patients with gastrointestinal bleeding are expanding. |
| | |
Authors:
|
Joseph R Pisegna |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Pharmacotherapy Volume: 23 ISSN: 0277-0008 ISO Abbreviation: Pharmacotherapy Publication Date: 2003 Oct |
Date Detail:
|
Created Date: 2003-10-31 Completed Date: 2004-02-27 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8111305 Medline TA: Pharmacotherapy Country: United States |
Other Details:
|
Languages: eng Pagination: 81S-86S Citation Subset: IM |
Affiliation:
|
Division of Gastroenterology and Hepatology, Veteran Affairs Greater Los Angeles Healthcare System at West Los Angeles, 11301 Wilshire Boulevard, CA 90073, USA. jpisegna@ucla.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles Adult Anti-Ulcer Agents / therapeutic use* Benzimidazoles / therapeutic use Clinical Trials as Topic Endoscopy, Gastrointestinal Gastric Acid / physiology, secretion Gastrointestinal Hemorrhage / diagnosis, drug therapy*, physiopathology Histamine H2 Antagonists / therapeutic use Humans Jehovah's Witnesses Male Omeprazole / analogs & derivatives Proton Pumps / antagonists & inhibitors Recurrence Risk Factors Sulfoxides / therapeutic use Zollinger-Ellison Syndrome / drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Ulcer Agents; 0/Benzimidazoles; 0/Histamine H2 Antagonists; 0/Proton Pumps; 0/Sulfoxides; 102625-70-7/pantoprazole; 73590-58-6/Omeprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pharmacologic properties of proton pump inhibitors.
Next Document: Acid suppression in critically ill patients: what does the evidence support?